Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 14/20 | 1.00 |
| ▸ | NPC1 | O15118 | 13/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 1.00 |
| ▸ | POLB | P06746 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | CASP3 | P42574 | 3/20 | 1.00 |
| ▸ | SENP7 | Q9BQF6 | 3/20 | 1.00 |
| ▸ | SENP6 | Q9GZR1 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | GAA | P10253 | 3/20 | 1.00 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 0.72 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.71 |
| ▸ | ABL1 | P00519 | 1/20 | 0.70 |
| ▸ | LCK | P06239 | 1/20 | 0.70 |
| ▸ | LYN | P07948 | 1/20 | 0.70 |
| ▸ | SRC | P12931 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5776766 | 1.00 | RAB9A (1.00) | RAB9ANPC1KDM4EPOLBALDH1A1 | |
| SCHEMBL3533833 | 0.84 | RAB9A (1.00) | RAB9ANPC1KDM4EPOLBALDH1A1 | |
| SCHEMBL3533832 | 0.84 | RAB9A (1.00) | RAB9ANPC1KDM4EPOLBALDH1A1 | |
| SCHEMBL17712436 | 0.83 | RAB9A (1.00) | RAB9ANPC1KDM4EPOLBALDH1A1 | |
| SCHEMBL16383880 | 0.83 | RAB9A (1.00) | RAB9ANPC1KDM4EPOLBALDH1A1 | |
| SCHEMBL1508832 | 0.80 | TUBB4A (1.00) | RAB9ANPC1KDM4EPOLBALDH1A1 | |
| SCHEMBL30725598 | 0.80 | TUBB4A (0.71) | RAB9ANPC1KDM4EPOLBALDH1A1 | |
| SCHEMBL1508835 | 0.80 | TUBB4A (1.00) | RAB9ANPC1KDM4EPOLBALDH1A1 | |
| SCHEMBL12692529 | 0.80 | RAB9A (1.00) | RAB9ANPC1KDM4EPOLBALDH1A1 | |
| SCHEMBL12066528 | 0.79 | TUBB4A (0.74) | RAB9ANPC1KDM4EPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9695193-B2 | Inhibitors of Plasmodium falciparum equilibrative nucleoside transporter type I as anti-parasitic compounds | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2017-07-04 | — | — | US | claimed |
| US-20160122362-A1 | INHIBITORS OF PLASMODIUM FALCIPARUM EQUILIBRATIVE NUCLEOSIDE TRANSPORTER TYPE I AS ANTI-PARASITIC COMPOUNDS | UNIV COLUMBIA (US) | 2016-05-05 | — | — | US | claimed |
| WO-2014210319-A2 | INHIBITORS OF PLASMODIUM FALCIPARUM EQUILIBRATIVE NUCLEOSIDE TRANSPORTER TYPE 1 AS ANTI-PARASITIC COMPOUNDS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2014-12-31 | — | — | WO | claimed |
| US-9695193-B2 | Inhibitors of Plasmodium falciparum equilibrative nucleoside transporter type I as anti-parasitic compounds | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2017-07-04 | — | — | US | disclosed |
| US-20160122362-A1 | INHIBITORS OF PLASMODIUM FALCIPARUM EQUILIBRATIVE NUCLEOSIDE TRANSPORTER TYPE I AS ANTI-PARASITIC COMPOUNDS | UNIV COLUMBIA (US) | 2016-05-05 | — | — | US | disclosed |
| EP-1558260-A4 | QUINAZOLINONE COMPOUNDS AS CALCILYTICS | NPS PHARMA INC (US) | 2006-10-25 | — | — | EP | disclosed |
| EP-1558260-A2 | QUINAZOLINONE COMPOUNDS AS CALCILYTICS | NPS PHARMACEUTICALS, INC. (US) | 2005-08-03 | — | — | EP | disclosed |
| WO-2004041755-A2 | QUINAZOLINONE COMPOUNDS AS CALCILYTICS | NPS PHARMACEUTICALS, INC. (US) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160122362-A1 | INHIBITORS OF PLASMODIUM FALCIPARUM EQUILIBRATIVE NUCLEOSIDE TRANSPORTER TYPE I AS ANTI-PARASITIC COMPOUNDS | SLC29A1, SLC29A2, SLC28A1 | RAB9A 1709/4885NPC1 144/4885KDM4E 3989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.